RxDoctor Payments Data

Barry Talesnick, MD

Cardiovascular Disease · Chevy Chase, MDNPI 1518964410

Payments from drug & device makers

$11,303in general payments, 2019–2025

Across 514 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Amgen$1K
  • Novartis$957
  • Boehringer Ingelheim$830
  • Johnson & Johnson$624
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$11,268100%
  • Education$350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,303 in reported general payments places this provider in the 80th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$547,317
Medicare patients
1,334
Services billed
5,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban417$458,472
XareltoRivaroxaban54$60,065
JardianceEmpagliflozin15$26,314
Repatha SureclickEvolocumab15$22,719
MultaqDronedarone Hcl19$22,413
EntrestoSacubitril/Valsartan11$21,927
Praluent PenAlirocumab11$14,650
Metoprolol Succinate499$11,815
Atorvastatin Calcium805$10,810
Rosuvastatin Calcium492$10,345
Olmesartan Medoxomil348$9,472
SynthroidLevothyroxine Sodium70$6,521
Amlodipine Besylate582$4,347
Losartan Potassium249$3,807
Levothyroxine Sodium240$3,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$1,259$459,902434 claims
Johnson & JohnsonXarelto$624$60,06554 claims
Boehringer IngelheimJardiance$830$26,31415 claims
Sanofi-aventis U.S. LLCMultaq$312$22,41319 claims
NovartisEntresto$957$21,92711 claims
AbbVieSynthroid$45$6,52170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →